Results 211 to 220 of about 60,277 (349)

Evaluation of Hemoadsorption Capacity of the CytoSorb Adsorber for Toxic Doses of Diclofenac and Meloxicam in Porcine Plasma

open access: yesJournal of Clinical Apheresis, Volume 41, Issue 3, June 2026.
ABSTRACT The objective of this in vitro experimental was to determine the utility of hemoadsorption (HA) using the CytoSorb adsorber to remove meloxicam and diclofenac from porcine plasma. For this purpose 12 1‐L aliquots of porcine plasma, 6 units were spiked with 293 μg/mL (262–320 μg/mL) diclofenac and 6 with 42.8 μg/mL (41.4–44.7 μg/mL) meloxicam ...
Bettina Giani   +3 more
wiley   +1 more source

Comparative renal risk of long-term use of beta-lactams in combination with vancomycin across the continuum of care. [PDF]

open access: yesTher Adv Infect Dis, 2023
Dolly LM   +6 more
europepmc   +1 more source

Protective effect of snail secretion filtrate in an in vitro model of mastitis

open access: yesVeterinary Record Open, Volume 13, Issue 1, June 2026.
Abstract Background Bovine mastitis is inflammation of the mammary gland mainly caused by bacterial infections, with relevant economic costs and implications related to antibiotic resistance. In light of the increasing demand for sustainable therapies, this study evaluated the anti‐inflammatory and antioxidant effects of snail secretion filtrate (SSF ...
Gianluca Antonio Franco   +5 more
wiley   +1 more source

Direct oral provocation test with beta-lactams in Brazilian children and adolescents. [PDF]

open access: yesJ Pediatr (Rio J)
de Almeida NMG   +3 more
europepmc   +1 more source

Is the Anamnesis Enough to De-Label Patients with Reported Beta-Lactam Allergy?

open access: green
Lesia Rozłucka   +3 more
openalex   +2 more sources

Epicutaneous and Drug Provocation Testing in Severe Cutaneous Adverse Reactions: A 20‐Year Single‐Centre Experience

open access: yesContact Dermatitis, Volume 94, Issue 6, Page 677-688, June 2026.
This study provides reassuring evidence in favour of early skin testing in patients with SCARs, argues against the necessity of a 6‐month delay, and underscores the pivotal role of oral provocation tests in the safe reintroduction of essential therapies. ABSTRACT Background Identifying and discontinuing the offending drug(s) in severe cutaneous adverse
Zohra Chadli   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy